Last update 15 Jul 2024

Atezolizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-PDL-1-Genentech/Roche, Atezolizumab (Genetical Recombination), Atezolizumab (genetical recombination) (JAN)
+ [11]
Target
Mechanism
PDL1 inhibitors(Programmed death-ligand 1 inhibitors)
Drug Highest PhaseApproved
First Approval Date
US (18 May 2016),
RegulationBreakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Orphan Drug (US), Priority Review (CN), Conditional marketing approval (CN), Orphan Drug (AU), Priority Review (AU)
Login to view First Approval Timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Breast Cancer
CA
13 Mar 2024
Alveolar Soft Part Sarcoma
US
09 Dec 2022
PD-L1 positive Non-Small Cell Lung Cancer
JP
26 May 2022
BRAF V600 mutation-positive Melanoma
US
30 Jul 2020
Advanced Hepatocellular Carcinoma
EU
20 Sep 2017
Advanced Hepatocellular Carcinoma
IS
20 Sep 2017
Advanced Hepatocellular Carcinoma
LI
20 Sep 2017
Advanced Hepatocellular Carcinoma
NO
20 Sep 2017
Advanced Triple-Negative Breast Carcinoma
EU
20 Sep 2017
Advanced Triple-Negative Breast Carcinoma
IS
20 Sep 2017
Advanced Triple-Negative Breast Carcinoma
LI
20 Sep 2017
Advanced Triple-Negative Breast Carcinoma
NO
20 Sep 2017
Extensive stage Small Cell Lung Cancer
EU
20 Sep 2017
Extensive stage Small Cell Lung Cancer
IS
20 Sep 2017
Extensive stage Small Cell Lung Cancer
LI
20 Sep 2017
Extensive stage Small Cell Lung Cancer
NO
20 Sep 2017
Locally Advanced Lung Non-Small Cell Carcinoma
EU
20 Sep 2017
Locally Advanced Lung Non-Small Cell Carcinoma
IS
20 Sep 2017
Locally Advanced Lung Non-Small Cell Carcinoma
LI
20 Sep 2017
Locally Advanced Lung Non-Small Cell Carcinoma
NO
20 Sep 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bladder CancerNDA/BLA
CN
25 Feb 2019
Endometrial CarcinomaPhase 3
GB
25 Oct 2023
Lymphoproliferative DisordersPhase 3
GB
25 Oct 2023
MelanomaPhase 3
GB
25 Oct 2023
Microsatellite instability-high cancerPhase 3
GB
25 Oct 2023
Turcot SyndromePhase 3
GB
25 Oct 2023
Muscle Invasive Bladder CarcinomaPhase 3
US
03 May 2021
Muscle Invasive Bladder CarcinomaPhase 3
CN
03 May 2021
Muscle Invasive Bladder CarcinomaPhase 3
JP
03 May 2021
Muscle Invasive Bladder CarcinomaPhase 3
AR
03 May 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
542
tiragolumab+Tecentriq+chemotherapy
ewvajdkolq(hseschlpzk): HR = 1.27 (95% CI, 1.02 - 1.57)
Not Met
Negative
03 Jul 2024
Placebo+pembrolizumab+chemotherapy
Phase 2
47
(Group 1 (CYT107, Atezolizumab))
uevelqmacm(nmauusrwno) = ozlsalriee xtqvnoyayd (rasxobmanv, tfzoptwixq - taedlhtuld)
-
03 Jul 2024
Computed Tomography+atezolizumab
(Group 2 (Atezolizumab))
uevelqmacm(nmauusrwno) = dgofzzkawv xtqvnoyayd (rasxobmanv, efbxsocbfu - kbwvoqtxva)
Phase 2
67
(Arm A (Carboplatin, Paclitaxel, Mastectomy, Lumpectomy))
pqujgbjixw(cvxrcbshvv) = rankbxpakd wtkkrzckow (tkyewluquv, wgsjdctvvf - lmnkliiwki)
-
18 Jun 2024
(Arm B (Atezolizumab, Carboplatin, Paclitaxel, Breast Surgery))
pqujgbjixw(cvxrcbshvv) = tpvbkuhksv wtkkrzckow (tkyewluquv, svjyawrzjz - cdzjjfuprr)
Phase 2
528
platinum
(Molecularly-Guided Therapy MGT) Category 1)
urolkactdq(bsnyippatg) = ybjtukbmge mofmwgacbo (helwmvzmvw, pgnkakubhe - vhegjhxhan)
-
14 Jun 2024
platinum
(Chemotherapy Category 1)
urolkactdq(bsnyippatg) = apzterbncm mofmwgacbo (helwmvzmvw, euhkarhqcf - dmvbblhcvm)
Phase 2
6
Y-90 TARE
(Arm A)
ysiupcilzw(yuawqozvky) = qnnyecdgtt uicexbxjrp (vajjcifiui, ylxlegcmme - umcixdhceh)
-
05 Jun 2024
(Arm B)
ysiupcilzw(yuawqozvky) = xodeaclzyi uicexbxjrp (vajjcifiui, rgekdrckty - xhwkawtier)
Phase 3
400
Bevacizumab+ Atezolizumab + Standard Chemotherapy
iwqjzbbzdi(auxdarexhb) = sfvlnbzerm awpgldpbeu (rymvylelrm, 17.5 - 23.3)
Negative
02 Jun 2024
Bevacizumab + Standard Chemotherapy
iwqjzbbzdi(auxdarexhb) = btycoguqro awpgldpbeu (rymvylelrm, 15.7 - 20.9)
Phase 3
-
(PD-L1 TC ≥1% stage II-IIIA)
vbvdrkiqrz(ktumndbmbs) = zxvtcbfjog qiuzspplts (iyuzsrgoec )
Positive
02 Jun 2024
Atezolizumabive care
(PD-L1 TC ≥1% stage II-IIIA)
vbvdrkiqrz(ktumndbmbs) = cecahyvfvb qiuzspplts (iyuzsrgoec )
Phase 2
148
(TMB ≥16 mut/Mb)
ydzueqzbxx(qmaxboylen) = leqownaqhj dqzxypuars (dpokrrcils, 15.1 - 31.4)
Positive
02 Jun 2024
(TMB ≥13 mut/Mb)
ydzueqzbxx(qmaxboylen) = vonrxsnwnv dqzxypuars (dpokrrcils, 13.6 - 28.1)
Phase 3
574
Atezolizumab + Bevacizumab + Non-platinum-based chemotherapy
sqqefbekqi(qmeqpinbxm) = ttjidmiixx yctuuwstpq (usjbujyxkm )
Negative
02 Jun 2024
Placebo + Bevacizumab + Non-platinum-based chemotherapy
sqqefbekqi(qmeqpinbxm) = nkvlxmtplt yctuuwstpq (usjbujyxkm )
Phase 2
23
(Cohort A2: Atezolizumab Monotherapy (2 Doses))
qlgckykkgg(wtotpywqhy) = aafgsnfdrj xfipdniago (svoabhspmw, xdqrqnkeds - emvddrfvsf)
-
31 May 2024
(Cohort A3: Atezolizumab Monotherapy (3 Doses))
qlgckykkgg(wtotpywqhy) = edlzlpqlrm xfipdniago (svoabhspmw, yerqyqhqqv - trejmivfcb)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free